A Harvard-lineage biotech with a genuinely new mechanism for solid tumor immunotherapy. The science is elegant and counterintuitive, make tumor cells look infected so the immune system already knows how to kill them. The site's job: make a PhD-level insight land in thirty seconds.
“Turning Tumors Into Infection Targets.” The hero leads with the whole idea in five words, set over a single arresting image of a tumor. No mechanism, no jargon, no buildup. A page this confident tells you what it believes before it explains how it works.
“The immune system knows how to kill tumors. It just needs to know where to look.” Then the honest read: checkpoint inhibitors, ADCs, CAR-Ts capped at 25–50%. You can’t claim a breakthrough without first naming plainly what fell short.
“A modular recombinant protein therapy that labels the target cell as if it were infected.” The whole counterintuitive idea, stated once, in plain language — selective, localized, non-immunosuppressive. The science is novel; the sentence refuses to hide behind that.
The ITC Trojan Horse platform reduced to a three-beat verb sequence, each step in its own cell. Complex biology, sequenced so a non-scientist follows it without losing the rigor. The restraint is the persuasion.
Lead program ORION™, HER2+ bladder cancer and head-and-neck squamous, in advanced preclinical. Named indications, not a platform daydream. Specificity is what separates a real pipeline from a pitch deck, and the page knows it.
“This isn’t a concept. It’s biology that already works.” P < 0.00076. A 30.5% → 1.1% shift in exhausted T-cells. 11× active T-cells. Set large, sourced precisely, no infographic dressing. Numbers that need decoration aren’t trusted.
Seasoned biotech operators, the inventor of the ITC platform, the discoverer of the p21 tumor suppressor. The bios are specific enough to be believed and brief enough not to be skipped. Authority that doesn’t raise its voice.
The footer restates the opening word for word: “Turning Tumors Into Infection Targets. The immunity is already there. We give it the target.” A brand with a real idea doesn’t need a louder closer — it just says the true thing twice.
Live at imyunpharma.com →
Every decision here keeps the user in frame while the work earns its trust. The system holds across every fold, which is the only test that matters.
It starts with an honest read of what you have now. No pitch.